Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Immune checkpoint inhibitors in resectable and locoregionally advanced HNSCC: past lessons, present evidence, and future directions. Local targets link to admitted publications; unresolved targets remain external evidence.
Head and neck cancer: a review
10.1001/jama.2025.21733 · 2026 · External reference
Head and neck cancer
10.1056/nejmra1715715 · 2020 · External reference
Changing landscape of head and neck squamous cell carcinoma and nasopharyngeal carcinoma treatment and survival trends in Thailand: a 13-Year multicenter retrospective study of patients
10.1200/go-24-00285 · 2025 · External reference
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
10.1056/nejmoa032646 · 2004 · External reference
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
10.1056/nejmoa032641 · 2004 · External reference
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
10.1002/hed.20279 · 2005 · External reference
Postoperative radiation with or without concurrent chemotherapy for patients with locally advanced head and neck squamous cell carcinoma with multiple intermediate risks: a propensity score-matched study
10.1002/cam4.70746 · 2025 · External reference
Meta-analysis of chemotherapy in head and neck cancer (mach-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC group
10.1016/j.radonc.2021.01.013 · 2021 · External reference
Unresolved reference
External reference
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
10.1056/nejmoa053422 · 2006 · External reference
The use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin based chemoradiation: landmark 3-year survival analysis of a randomized phase III trial (DHANUSH)
10.1200/jco.2025.43.16_suppl.6086 · 2025 · External reference
Pan-Asian adaptation of the EHNS-ESMO-ESTRO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
10.1016/j.esmoop.2021.100309 · 2021 · External reference
Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma
10.1016/j.oraloncology.2023.106520 · 2023 · External reference
Early recurrence, time-to-recurrence, and recurrence patterns: assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy
10.1002/cam4.7047 · 2024 · External reference
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study
10.1200/jco.21.02508 · 2023 · External reference
Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer
10.1056/nejmoa2415434 · 2025 · External reference
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
10.1016/s0140-6736(25)01850-1 · 2026 · External reference
Perioperative camrelizumab plus chemotherapy in locally advanced squamous cell carcinoof thead and neck (CAMORAL): a multicenter, open-label, randomized, phase II Study
10.1016/j.annonc.2025.08.1951 · 2025 · External reference
A phase II exploratory study (NCT06208826) on maintenance immunotherapy in patients with resectable locally advanced head and neck cancer who achieved MPR after neoadjuvant immunotherapy combined with chemotherapy
10.1200/jco.2025.43.16_suppl.e18083 · 2025 · External reference
Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: preliminary results of INSIGHT study
10.1200/jco.2023.41.16_suppl.6068 · 2023 · External reference
Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma
10.1200/jco.2025.43.16_suppl.6084 · 2025 · External reference
Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: a randomized, open label, phase II clinical trial
10.1200/jco.2025.43.16_suppl.6043 · 2025 · External reference
Neoadjuvant PD-1 inhibitor combined with nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): a randomized, controlled, open label, phase II clinical trial
10.1200/jco.2025.43.16_suppl.6018 · 2025 · External reference
A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck
10.1200/jco.2023.41.16_suppl.6069 · 2023 · External reference
Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial
10.1016/j.esmoop.2025.105505 · 2025 · External reference
Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial
10.1038/s41467-025-59865-1 · 2025 · External reference
Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer
10.1200/jco.2020.38.15_suppl.6583 · 2020 · External reference
Atezolizumab in High-Risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial
10.1001/jama.2025.1483 · 2025 · External reference
Postoperative adjuvant radiochemotherapy with cisplatin (aRCH) vs. aRCH plus pembrolizumab in locally advanced head and neck squamous cell carcinoma (HNSCC): first data of the ADRISK trial
2018 · External reference
Survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin
10.1200/jco.2024.42.16_suppl.6099 · 2024 · External reference
co + oropharynx cancer
10.1200/jco.2023.41.16_suppl.6014 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck cancer (LA HNSCC) in the Asian subgroup of the phase III KEYNOTE-689 trial
10.1016/j.annonc.2025.10.1103 · 2025 · External reference
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
10.1038/s43018-025-00990-7 · 2025 · External reference
Mounting evidence for perioperative immunotherapy
10.1038/s41591-023-02710-z · 2023 · External reference
Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen–specific T cells
10.1158/1078-0432.ccr-19-2209 · 2020 · External reference
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
10.1038/s41571-024-00969-w · 2025 · External reference
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
10.1016/j.cell.2022.06.018 · 2022 · External reference
Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease
10.1200/edbk_349411 · 2022 · External reference
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
10.1136/jitc-2024-010833 · 2025 · External reference
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial
10.1038/s41467-024-46444-z · 2024 · External reference
Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): an open-label, single-arm, phase 2 study
10.1200/jco.2024.42.16_suppl.6073 · 2024 · External reference
Proceedings of the national cancer institute workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
10.1016/s1470-2045(24)00656-9 · 2025 · External reference
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers
10.1016/j.ctrv.2022.102361 · 2022 · External reference
Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations
10.1200/edbk_351336 · 2022 · External reference
Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)
10.1200/jco.2025.43.16_suppl.6013 · 2025 · External reference
Results from CompARE phase III RCT: neoadjuvant durvalumab plus chemoradiotherapy followed by adjuvant durvalumab vs chemoradiotherapy alone in intermediate- and high-risk oropharyngeal cancer
2025 · External reference
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
10.1016/s1470-2045(20)30737-3 · 2021 · External reference
854MO avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final analysis of randomized phase III GORTEC 2017-01 REACH trial
10.1016/j.annonc.2024.08.915 · 2024 · External reference
Interim futility results of NRG-HN005, a randomized, phase II/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients
10.1016/j.ijrobp.2024.08.014 · 2024 · External reference
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
10.1136/jitc-2021-003747 · 2022 · External reference
Randomized phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer
10.1200/jco-24-01580 · 2025 · External reference
Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized clinical trial
10.1001/jamaoncol.2024.1530 · 2024 · External reference
Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in HPV-negative head and neck cancer: the DEPEND phase 2 nonrandomized clinical trial
10.1001/jamaoncol.2025.0081 · 2025 · External reference
Camrelizumab plus apatinib as induction therapy for locally advanced head and neck squamous cell carcinoma (IMplus): a single-arm phase II study
10.1200/jco.2022.40.16_suppl.6060 · 2022 · External reference
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
10.1016/s1470-2045(24)00507-2 · 2024 · External reference
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
10.1016/j.annonc.2022.10.006 · 2023 · External reference
Concurrent definitive immunoradiotherapy for patients with stage III-IV head and neck cancer and cisplatin contraindication
10.1158/1078-0432.ccr-20-0230 · 2020 · External reference
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
10.1056/nejmoa1709937 · 2017 · External reference
Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non–small cell lung cancer: the phase III PACIFIC-2 study
10.1200/jco-25-00036 · 2025 · External reference
The tumor-sentinel lymph node immuno-migratome reveals CCR7+ dendritic cells drive response to sequenced immunoradiotherapy
10.1038/s41467-025-61780-4 · 2025 · External reference
Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
10.1158/1078-0432.ccr-17-3427 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
10.1016/j.ejca.2024.115055 · 2024 · External reference
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce
10.1136/jitc-2019-000398 · 2020 · External reference
A phase 3, prospective, multicenter, randomized open-label trial to compare the efficacy and safety of tislelizumab (BGB-A317, Anti–PD-1 antibody) combined with chemotherapy followed by surgery versus up-front surgery as treatment for resectable head and neck squamous cell carcinoma
10.1200/jco.2018.36.15_suppl.tps3110 · 2018 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
945tip JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
10.1016/j.annonc.2024.08.2145 · 2024 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer
10.1016/s1470-2045(25)00020-8 · 2025 · External reference
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts)
10.1200/jco.2025.43.16_suppl.6016 · 2025 · External reference
Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis
10.1200/jco.2023.41.16_suppl.6075 · 2023 · External reference
Phase I dendritic cell p53 peptide vaccine for head and neck cancer
10.1158/1078-0432.ccr-13-2617 · 2014 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Phase II trial of neoadjuvant chemotherapy (NAC) docetaxel-cisplatin alone (DC) or with anti-human papillomavirus (HPV) gene therapy PRGN-2009 (DCP) followed by surgery in patients (pts) with newly diagnosed HPV-Associated oropharyngeal cancer (HPV-OPC)
10.1200/jco.2025.43.16_suppl.tps6117 · 2025 · External reference
Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC)
10.1200/jco.2023.41.16_suppl.tps6115 · 2023 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Circulating tumour DNA in head and neck squamous-cell carcinomas: a literature review
10.1016/j.ctrv.2025.103070 · 2026 · External reference
Circulating tumor DNA in non-viral head and neck squamous cell carcinoma: a systematic review and meta-analysis
10.1016/j.oraloncology.2025.107760 · 2025 · External reference
ctDNA and recurrence risk for adjuvant de-escalation in HPV-positive oropharyngeal carcinoma: a secondary analysis of the DART phase 3 randomized clinical trial
10.1001/jamaoto.2025.0903 · 2025 · External reference
Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)
10.1016/j.esmoop.2025.104534 · 2025 · External reference
Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients
10.1038/s41698-026-01309-0 · 2026 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2026 · External reference
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy
10.1038/s41698-024-00759-8 · 2024 · External reference
Spatial profiling of HPV-stratified head and neck squamous cell carcinoma reveals distinct immune niches and microenvironmental architectures
10.1186/s12967-025-07280-x · 2025 · External reference
Neoadjuvant chemotherapy combined with anti-PD-1 monoclonal antibody in locally advanced resectable oral squamous cell carcinoma: efficacy evaluation and prediction
10.1016/j.oraloncology.2025.107744 · 2025 · External reference
Six-microRNA prognostic signature in patients with locally advanced head and neck squamous cell carcinoma
10.1200/po.23.00003 · 2023 · External reference
